Glaucoma, a serious eye disease that is thought to affect approximately two per cent of the world population over the age of 40, is now being treated by a totally new concept in drug delivery.
DR. U. SILENT
DR. URQUHART ON CAMERA WHILE HE INSERTS OCUSERTR INTO EYE
Script is copyright Reuters Limited. All rights reserved
Background: Glaucoma, a serious eye disease that is thought to affect approximately two per cent of the world population over the age of 40, is now being treated by a totally new concept in drug delivery.
This is the OCUSERTR System, now being manufactured by its developer, ALZA Corporation, a california pharmaceutical company.
Dr. John Urquhart (ERK-HARD) explains:
(DR. URQUHART) "The OCUSERTR System delivers the drug pilocarpine continuously to the eye for a period of seven days. It's a small membrane system, very thin and flexible, which is very easily put against the white of the eye, placed beneath either the lower or upper eyelid, floats on the tear film and delivers the drug continuously over a seven-day period."
The System consists of two thin polymer membranes surrounding a film which contains a reservoir of drug commonly used in glaucoma treatment. The membranes release minute amounts of the drug at precise and controlled dosages to the eye for a period of one week. The System, which works on a unique concept ALZA scientist have been developing for six years, requires highly specialized manufacturing techniques. By using the OCUSERTR System to treat glaucoma, a sight-threatening disease, the patient may no longer suffer some of the adverse effects of eyedrop therapy, which can cause blurred vision after each instillation. Besides glaucoma, ALZA scientists are working on a similar treatment for trachoma, which is the world's leading cause of blindness.